As one of the most attractive and lucrative markets in the Middle East, Saudi Arabia brings a strong opportunity for pharmaceutical and biotech manufacturers to obtain high prices and uptake within the GCC region, where price referencing against Saudi Arabia is key.

The opportunity in Saudi Arabia can be characterized by the major factors contributing to commercial success:

Price: New pricing guidelines and the reorganization of the reference basket list have made pricing flexible; where products are launched in Saudi Arabia immediately after the US are able to reference US prices as the country of origin

Market Access: Broad, unrestricted access is feasible for the national population (60%-65% of the total population), with no payer restrictions at the national level

Volume: High relative volume of patients, particularly within rare diseases, where consanguinity has played in a role in the increase of genetic disorders